HER2-低乳腺癌:当前的景观和未来的前景
Yelena Shirman1, Shlomit Lubovsky1, Ayelet Shai1
1Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
Breast cancer (Dove Medical Press)
|August 21, 2023
概括
超过50%的乳腺癌是低HER2,表达人体表皮生长因子受体2 (HER2) 的低水平. 这些癌症是抗体药物合物 (ADC) 的关键目标,尽管存在诊断方面的挑战.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 超过50%的乳腺癌 (BC) 被归类为HER2-低 (IHC +1或+2,FISH负).
- 与HER2-阴性BC相比,HER2-低BC往往缺乏独特的临床/分子特征.
- 在这些瘤中,HER2的主要意义似乎是作为抗体药物合物 (ADC) 的标.
研究的目的:
- 审查最近关于低HER2乳腺癌的文献.
- 为了将临床和翻译研究置于背景中.
- 讨论评估HER2表达和治疗场景的挑战.
主要方法:
- 对HER2-低乳腺癌的临床和转化研究的文献综述.
- 分析目前用于HER2评估的病理方法.
- 对针对低HER2乳腺癌的治疗策略的审查.
主要成果:
- 低HER2的BC占乳腺癌病例的很大一部分.
- 由于异质性和分析限制,目前的病理学方法可能会低估HER2低患病率.
- 低HER2的BC作为ADC的关键目标.
结论:
- 精确评估低HER2表达的情况至关重要.
- 低HER2的BC代表着一个独特的治疗机会,特别是在ADCs.
- 需要进一步的研究来优化 HER2 低乳腺癌的诊断和治疗.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.7K
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.7K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Survival Analysis
383
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
383
